In the most recent cohort study including 869 children with AML from the TARGET data set, NPM1 mutation was associated to a superior outcome regardless of FLT3-ITD status and constituted an independent predictor of a favorable prognosis (Xu et al., 2020). This evidence concerns the gene FLT3 and acute myeloid leukemia.